Abstract. Several types of transient thyroid dysfunction in infants born to mothers with Graves' disease have been described, ranging from completely unaffected infants to those with hyperthyroidism or hypothyroidism, depending on maternal thyroid function, activity of maternal TSH receptor antibody (TRAb) and maternal antithyroid agents due to transplacental passage. We observed a premature neonate born to a mother with three-year-untreated Graves' disease, who developed transient central hypothyroidism in the immediate postnatal period. Placental transfer of thyroxine and TRAb from the thyrotoxic mother may cause fetal peripheral thyrotoxicosis resulting in suppression of the fetal pituitarythyroid axis.
Introduction
F e m al es w it h G ra v e s ' d i s e a s e a r e recommended to conceive in a condition of euthyroidism and decreased TSH receptor antibody (TRAb), because transplacental passage of thyroxine, TRAb and antithyroid medication disturb the fetal neuropsycho-intellectual development (1, 2) . Neonatal thyrotoxicosis is caused by transplacental passage of maternal TRAb.
Transient central hypothyroidism in infants born to mothers with Graves' disease, most of whom have had no treatment, is a unique disorder first reported by Matsuura et al. in 1988 (3) . Here we report transient central hypothyroidism resulting from pituitary suppression in a premature neonate born to a mother with threeyear-untreated Graves' disease; transient central h y p o t hy r o i d i s m d e v e l o p e d a f t e r f e t a l thyrotoxicosis.
Case Report
A female neonate was born at 32 wk 6 d of gestational age to a 29-yr-old mother who was diagnosed at 26 yr of age as having Graves' disease, but not treated due to poverty. Premature rupture of the membranes occurred at 32 wk 4 d and the fetal heart rate was from 140 to 160 beats per min. At the time of delivery, the mother had thyrotoxicosis. Her serum free T 3 concentration was 11.0 pg/ml, free T 4 4.4 ng/dl, TSH <0.002 µIU/ ml, and TRAb 45.5%. The neonate had a 1-min Apgar score of 8, weighed 2229 g, and had no clinical signs of thyrotoxicosis (tachycardia, exophthalmos and goiter) or hypothyroidism (poor suck, hypotonia, edema, grunting, cyanosis and peripheral coldness). Ultrasonographic study detected normal size of thyroid (Fig. 1) . Serum free T 3 concentration of the cord blood was 1.4 pg/ ml, free T 4 1.3 ng/dl, TSH <0.002 µIU/ml, TRAb 40.4%, thyroid-stimulating antibody (TSAb) 523%. Radiographic study of hand bone and distal femoral epiphyseal center revealed acceleration of bone maturation ( Fig. 2A and 2B ). On day 7, serum concentration of free T 4 had fallen to 0.8 ng/dl (Table 1) . L-thyroxine therapy (5 µg/kg per day) was administered on day 11 and the dose of Lthyroxine was increased to 10 µg/kg per day on day 15. The baby's free T 3 , free T 4 and TSH levels were normalized on day 21. At 7 mo of age, the dose of L-thyroxine was decreased to 2 µg/kg per day. At 1 yr of age, the patient's weight, length and head circumference were between the 50th to 75th centiles and her neurological development was normal. L-thyroxine therapy was discontinued at that time. One month later, the patient's TSH, free 
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T 3 and free T 4 were 2.14, 3.6 and 1.2 respectively, suggesting transient central hypothyroidism and recovery of the thyroid axis, although the TRH administration test was not performed.
Discussion
Infants born to mothers with poorly controlled Graves' disease might have transient central hypothyroidism manifested by low free T 4 levels with inappropriately normal or low TSH levels in the cord blood and at day 5 (3-6). Matsuura et al. showed that the dried blood free T 4 levels in such infants were higher at birth than five days later, suggesting that the fetal pituitarythyroid axis was suppressed due to transfer of T 4 from mothe r t o fe tus re sul ti ng i n feta l thyrotoxicosis (Fig. 3) (7) . As illustrated in our case, in consideration of the advanced bone maturation at birth which is different from infants with congenital central hypothyroidism who demonstrate low free T 4 and TSH, it was apparent that this premature infant had fetal thyrotoxicosis caused by maternal thyroxine and strong TSAb activity for a relatively long time. After birth, she had central hypothyroidism, probably resulting from fetal transient thyrotoxicosis and marked decrease of TSAb activity. Kung and Jones showed that in Graves' disease patients during pregnancy, a change in specificity from stimulatory to blocking antibodies was observed (8) .
Fetal thyrotoxicosis is well known to occur when maternal hyperthyroidism is not properly treated during pregnancy due to strong TSAb activity. The same as in previous reports, the TRAb activity in our case varied from potent to weak. It is considered that low levels of maternal TRAb are not likely to be the cause of postulated fetal thyrotoxicosis in these infants. In our case TRAb might have caused fetal thyrotoxicosis, because during pregnancy her mother might have had higher levels of TRAb activity. Infants born to mothers with sufficiently strong activity of TRAb (TRAb>60%, TSAb>600-800%; Momotani, in Japanese) might remain euthyroid or have thyrotoxicosis even in the presence of suppressed TSH secretion, whereas those with weak TRAb activity might have central hypothyroidism. Matsuura et al. (7) and Hashimoto et al. (9) reported that central hypothyroidism might become overt when TSAb activity was relatively weak in comparison with TRAb activity after birth. The difference of specific epitopes for binding to TSH receptors between TRAb and TSAb may cause th is di ssociation, a nd the d ifference i n responsiveness to the TSAb between the maternal and fetal thyroids may cause this dissociation between mothers and infants (10). However our findings were not similar in that the dissociation between TRAb and TSAb activities was not observed: the cord blood TRAb level was 40.4% and TSAb level was 523%.
Although our case was a premature infant, previous reports have noted gestational ages of neonates of transient hypothyroidism ranging from 27 wk to 41 wk. The activity of TSAb is believed to fall as gestation progress (8) . Therefore, there should be no direct relationship b etw een pr ematu r e b ir th and t ra nsient hypothyroidism.
Neonatal transient central hypothyroidism secondary to maternal uncontrolled Graves' disease with thyrotoxicosis is not a novel event, but it is not widely recognized. We suggest that transient central hypothyroidism may occur in infants born to untreated mothers with Graves' disease, and is caused by pituitary suppression after fetal transient peripheral thyrotoxicosis and decrease of TSAb activity. In such infants, the blood free T 4 levels at birth are higher than those at 5 day of age. Onigata reported two cases born to untreated mothers with Graves' disease presenting permanent central hypothyroidism (in Japanese). It has been shown that in the adult rat, transient neonatal hyperthyroidism leads to a permanent resetting of the regulatory set-point for pituitary TSH secretion and to increased sensitivity to the feedback inhibitory effects of thyroid hormones by Dussault and Walker (11, 12) . Accordingly long term follow up of the thyroid function and neuropsycho-intellectual developmental outcome is necessary.
